α-MSH related compounds and methods of use

Details α-MSH related compounds and methods of use α-MSH related compounds and methods of use

2007-01-30

2007-01-30

Kemmerer, Elizabeth (Department: 1649)

Chemistry: molecular biology and microbiology

Vector, per se

C435S069700, C435S069100, C536S023100, C536S023400, C536S024100

Reexamination Certificate

active

09906206

ABSTRACT:
The invention provides polypeptides containing α-MSH that can be used to treat diseases characterized by inflammation and/or autoimmunity. Also included in the invention are α-MSH analogs and nucleic acids encoding polypeptides containing α-MSH and α-MSH analogs optionally linked to heterologous sequences. Also included in the invention are methods of delivering α-MSH containing peptides, α-MSH analogs, an DNA encoding α-MSH and α-MSH analogs.

REFERENCES:
patent: 4675382 (1987-06-01), Murphy
patent: 5374548 (1994-12-01), Caras
patent: WO 90/06369 (1990-06-01), None
patent: WO 93/02692 (1993-02-01), None
patent: WO 99/57148 (1999-11-01), None
patent: WO 99/60135 (1999-11-01), None
patent: WO 00/33658 (2000-06-01), None
patent: WO 00/42856 (2000-07-01), None
Kezuka T, Streilein JW. Invest Ophthalmol Vis Sci. Jun. 2000;41(7):1803-11. In vitro generation of regulatory CD8+ T cells similar to those found in mice with anterior chamber-associated immune deviation.
Brandenburger et al. J Recept Signal Transduct Res. Jan.-Jul. 1999; 19: 467-480.
Dorr et al. Life Sci. 1996;58(20):1777-84.
Airaghi et al., “Elevated concentrations of plasma α-melanocyte stimulating hormone are associated with reduced disease progression in HIV-infected patients,” Lab. Clin. Med. 133(3):309-315 (Mar. 1999).
Catania et al., “The Neuropeptide α-MSH in HIV Infection and Other Disorders in Humans,” Ann. NY Acad. Sci., 840:848-856 (1998).
Cone et al., “The Melanocortin Receptors: Agonists, Antagonists, and the Hormonal Control of Pigmentation,” Recent Progress in Hormone Res., 51:287-318 (1996).
Cool et al., “Carboxypeptidase E Is a Regulated Secretory Pathway Sorting Receptor: Genetic Obliteration Leads to Endocrine Disorders in CpefatMice,” CELL, 88(1):73-83(Jan. 10, 1997).
Fan et al., “Role of melanocortinergic neurons in feeding and the agouti obesity syndrome,” NATURE, 385(6612):165-168 (Jan. 9, 1997).
Funasaka et al., “Expression of Proopiomelanocortin, Corticotropin-Releasing Hormone (CRH), and CRH Receptor in Melanoma Cells, Nevus Cells, and Normal Human Melanocytes,” J. Invest. Dermatol. Symp. Proc., 4(2):105-109 (Sep. 1999).
Hohmann et al., “Differential role of melanocortins in mediating leptin's central effects on feeding and reproduction,” Amer. J. Physiol., 278(1):R50-R59 (Jan. 2000).
Ichiyama et al., “Autocrine α-Melanocyte-Stimulating Hormone Inhibits NF-κB Activation in Human Glioma,” J. Neurosci. Res., 58(5):684-689 (Dec. 1, 1999).
Joosten et al., “Alpha-Melanocyte Stimulating Hormone Promotes Regrowth of Injured Axons in the Adult Rat Spinal Cord,” J. Neurotrauma, 16(6):543-553 (1999).
Kim et al., “ARC POMC mRNA and PVN α-MSH are lower in obese relative to lean Zucker rats,” Brain Res., 862:11-16 (Apr. 2000).
Korner et al., “Regulation of Hypothalamic Proopiomelanocortin by Leptin in Lean and Obese Rats,” NEUROENDOCRINOLOGY, 70:377-383 (Dec. 1999).
Krude et al., “Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused byPOMCmutations in humans,” Nature Genetics, 19(2):155-157 (Jun. 1998).
Lankhorst et al., “Functional Recovery After Central Infusion of α-Melanocyte-Stimulating Hormone in Rats with Spinal Cord Contusion Injury,” J. Neurotrauma, 16(4):323-331 (1999).
Lankhorst et al., “Combined treatment with a MSH and methylprednisolone fails to improve functional recovery after spinal injury in the rat,” Brain Research, 859:334-340 (2000).
Marsh et al., “Response of melanocortin-4 receptor-deficient mice to anorectic and orexigenic peptides,” Nature Genetics, 21:119-122 (Jan. 1999).
McMinn et al., “Effect of intracerebroventricular α-MSH on food intake, adiposity, c-Fos induction, and neuropeptide expression,” Amer. J. Physiology, 279(2):R695-R703 (Aug. 2000).
Mountjoy et al., “Obesity, Diabetes and Functions for Proopiomelanocortin-derived Peptides,” Mol. Cell Endocrinol., 128(1,2):171-177 (1997).
Rheins et al., “Alpha-Melanocyte Stimulating Hormone Modulates Contact Hypersensitivity Responsiveness in C57/BL6 Mice,” J. Investigative Dermatology, 93(4):511-517 (Oct. 1989).
Saperstein et al., “Interlekin 1β Mediates Stress-Induced Immunosuppression Via Corticotropin-Releasing Factor,” Endocrinol., 130(1):152-158 (Jan. 1992).
Schwartz et al., “Leptin Increases Hypothalamic Pro-opiomelanocortin mRNA Expression in the Rostral Arcuate Nucleus,” Diabetes, 46(12):2119-2123 (Dec. 1997).
Tam et al., “The amino-terminal sequence of pro-opiomelanocortin directs intracellular targeting to the regulated secretory pathway,” Eur. J. Cell Biol., 62(2):294-306 (Dec. 1993).
Taylor et al., “Alpha-Melanocyte-Stimulating Hormone Suppresses Antigen-Stimulated T Cell Production of Gamma-Interferon,” NEUROIMMUNOMODULATION, 1:188-194 (1994).
Thiele et al., “Central infusion of melanocortin agonist MTII in rats: assessment of c-Fos expression and taste aversion,” Amer. J. Physiol., 274(1):R248-R254 (Jan. 1998).
Vergoni et al., “Chronic melanocortin 4 receptor blockage causes obesity without influencing sexual behavior in male rats,” J. Endocrinology, 166(2):419-426 (Aug. 2000).
Yaswen et al., “Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin,” Nature Medicine, 5(9):1066-1070 (Sep. 1999).
Yeo et al., “The role of melanocortin signalling in the control of body weight: evidence from human and murine genetic models,” QJMed., 93(1):7-14 (Jan. 2000).
Zemel & Shi, “Pro-opiomelanocortin (POMC) Deficiency and Peripheral Melanocortins in Obesity,” Nutr. Rev., 58(6):177-180 (Jun. 2000).
“Oklahoma Medical Research Foundation: Obesity Breakthrough: Lessons From Fat Yellow Mice” http://www8.techmall.com/techdocs/TS990830-4.html (1999).
“Mutant Mice Provide Insight Into Obesity” http://www.omrf.ouhsc.edu/omrf
ews—releases/releases/19990831b.asp (1999).
“Worth the Weight” omrf.ouhsc.edu/omrf
ews—releases/releases/19990831.asp (1999).
Bishai et al. (1987) “High-level expression of a proteolytically sensitive diphtheria toxin fragment inEscherichia coli” J. Bacteriol. 169(11):5140-51.
Rajora et al. (1997) “Alpha-MSH modulates experimental inflammatory bowel disease” Peptides 18(3):381-85.
Taylor et al. (2000) “Alpha-melanocyte stimulating hormone (α-MSH) induction of regulatory autoreactive T cells” FASEB Journal 14(6):A1112, Abstract No. 140.5.
Mizuno et al., “Hypothalmaic pro-opiomelanocortin mRNA is reduced by fasting and inob/obanddb/dbmice, but is stimulated by leptin,” Diabetes, 47:696 (1998).

Affiliated with

Also associated with

Rating

α-MSH related compounds and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with α-MSH related compounds and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and α-MSH related compounds and methods of use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3769384